Since starting dapagliflozin, the patient has experienced profuse sweating, headache, dry cough, and fatigue; are these symptoms side effects of dapagliflozin?

Profuse Sweating and Headache Are Likely Side Effects of Dapagliflozin; Dry Cough and Fatigue Require Further Evaluation

The profuse sweating and headache your patient is experiencing are recognized side effects of dapagliflozin, particularly when associated with hypoglycemia, while the dry cough is not a typical side effect and warrants investigation for alternative causes. 1

Direct Side Effects from FDA Drug Label

According to the FDA drug label, dapagliflozin can cause hypoglycemia (low blood sugar), especially when combined with insulin or sulfonylureas. The classic symptoms of hypoglycemia explicitly include:

• Headache
• Sweating (profuse sweating)
• Confusion
• Weakness
• Dizziness
• Fast heartbeat 1

Your patient's profuse sweating and headache fit this hypoglycemia profile perfectly. Check if the patient is on concurrent insulin or sulfonylurea therapy, as this dramatically increases hypoglycemia risk and may require dose reduction of these medications.

Symptoms NOT Listed as Common Side Effects

The FDA label lists the most common side effects of dapagliflozin as:

• Vaginal yeast infections and penile yeast infections
• Stuffy or runny nose and sore throat
• Changes in urination 1

Notably absent from this list are dry cough and fatigue. While fatigue could theoretically relate to volume depletion or hypoglycemia, dry cough is not a recognized side effect of SGLT2 inhibitors.

Clinical Approach to These Symptoms

Immediate Actions:

1. Check blood glucose levels - Document if hypoglycemic episodes are occurring, particularly timing relative to symptoms
2. Review concurrent medications - If on insulin or sulfonylureas, consider reducing doses by approximately 20% for insulin or weaning sulfonylureas 2
3. Assess volume status - Check orthostatic vital signs, as volume depletion can cause fatigue and sweating 2

Investigate Alternative Causes:

• Dry cough: Consider ACE inhibitor use (if patient is on one), respiratory infection, or cardiac causes given the likely heart failure indication for dapagliflozin
• Fatigue: Could represent worsening heart failure, anemia, thyroid dysfunction, or medication effects from other drugs

Important Safety Considerations

The FDA label emphasizes monitoring for:

• Serious urinary tract infections - Can present with fatigue and systemic symptoms
• Volume depletion - More common in patients ≥75 years old (3.1% vs 2.6% placebo) 3
• Renal function changes - Particularly in older patients, though usually transient 3

If the patient has fever along with fatigue and discomfort, immediately evaluate for serious infections including necrotizing fasciitis of the perineum (rare but serious) or urinary tract infections. 1

Evidence on Tolerability

Long-term safety data shows dapagliflozin is generally well-tolerated, with adverse events increasing with age but serious adverse events remaining similar to placebo across age groups 3. In real-world HFrEF populations, hypotension (12.9%) was the most common adverse effect, with severe reactions occurring in only 3.9% of patients 4.

Bottom Line Management

Attribute the profuse sweating and headache to dapagliflozin-induced hypoglycemia until proven otherwise. Adjust concurrent glucose-lowering medications accordingly. The dry cough requires separate investigation - check for ACE inhibitor use, obtain chest imaging if indicated, and consider cardiac causes. Continue dapagliflozin if symptoms resolve with medication adjustments, as the cardiovascular and renal benefits are substantial 5, 4, 6.